<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03433430</url>
  </required_header>
  <id_info>
    <org_study_id>C-17-TS16</org_study_id>
    <nct_id>NCT03433430</nct_id>
  </id_info>
  <brief_title>Multi-Center Pilot Study of truSculpt Device</brief_title>
  <official_title>This is an Exploratory Multi-center, Pilot Study to Evaluate the Safety, Efficacy and Ergonomics of Cutera truSculpt Device. Subjects May Receive up to Three Treatments and Will be Followed at 12 Weeks Post the First and Final Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cutera Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cutera Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An exploratory pilot study to evaluate the safety, efficacy and ergonomics of Cutera
      truSculpt device
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, pilot study in approximately 40 subjects, ages 18 to 65. Subjects may
      receive up to three treatments and will be followed at 12 weeks post the first and final
      treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 17, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and Severity of adverse events</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Identification and Severity of treatment emergent Adverse Events (AE) where 1=Mild (requires minimal or no treatment and does not interfere with the subject's daily activities), 2=Moderate (may cause some interference with functioning) and 3=Severe (interrupts subject's usual daily activity and may require treatment).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Volumetric Comparison of Circumferential measurement in cm</measure>
    <time_frame>Comparison of baseline to 12 weeks post first treatment, and to 12 weeks post final treatment</time_frame>
    <description>Difference in circumferential measurement in cm from baseline and at 12 weeks post first and final treatments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ultrasound Comparison of Subcutaneous fat measurements</measure>
    <time_frame>Comparison of baseline to 12 weeks post first treatment, and to 12 weeks post final treatment</time_frame>
    <description>Difference in Subcutaneous fat measurement from baseline and at 12 weeks post first and final treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Temporal Photo Identification</measure>
    <time_frame>Comparison of Baseline to 12 weeks post first treatment, and to 12 weeks post final treatment</time_frame>
    <description>Correct identification of the 12 weeks post first and final treatment photographs from the baseline by at least two of the three blinded reviewers in 75% of the subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Fat Assessment by blinded reviewer</measure>
    <time_frame>At 12 weeks post first treatment and at 12 weeks post final treatment</time_frame>
    <description>Blinded improvement assessments of body fat as assessed by blinded reviewers using the Global Aesthetic Improvement Scale (GAIS:) +4=Very Significant Improvement (76 - 100%), +3=Significant Improvement(51 - 75%), +2=Moderate Improvement (26 - 50%), +1=Mild Improvement (6 - 25%), and 0=No Change (0 - 5%) at 12 weeks post the first and final treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Fat Assessment by Investigator</measure>
    <time_frame>At 12 weeks post first treatment and at 12 weeks post final treatment</time_frame>
    <description>Degree of Improvement in body fat as assessed by Investigator using the Global Aesthetic Improvement Scale (GAIS:) +4=Very Significant Improvement (76 - 100%), +3=Significant Improvement(51 - 75%), +2=Moderate Improvement (26 - 50%), +1=Mild Improvement (6 - 25%), and 0=No Change (0 - 5%)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Bulging</condition>
  <condition>Body Fat</condition>
  <arm_group>
    <arm_group_label>truSculpt</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>truSculpt treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>truSculpt</intervention_name>
    <description>Subjects will receive up to three treatments and will be followed at 12 weeks post the first and final treatment.</description>
    <arm_group_label>truSculpt</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must be able to read, understand and sign the Informed Consent Form.

          2. Female or Male, 18 to 65 years of age (inclusive).

          3. Subject has visible fat bulges in the area to be treated.

          4. Non-smoking for at least 6 months and willing to refrain from smoking for the duration
             of the study.

          5. Subject must agree to not undergo any other procedure(s) in the treatment region
             during the study period.

          6. Subject must adhere to the follow-up schedule and study instructions.

          7. Subject must adhere to the same diet and/or exercise routine throughout the study, and
             agree to maintain the same weight throughout the study.

          8. Willing to have digital photographs taken of the treatment area and agree to use of
             photographs for presentation, (educational and/or marketing), publications, and any
             additional marketing purposes.

          9. For female subjects: not pregnant or lactating and is either post-menopausal,
             surgically sterilized, or using a medically acceptable form of birth control at least
             3 months prior to enrollment and during the entire course of the study.

        Exclusion Criteria:

          1. Participation in a clinical trial of another device or drug within 3 months of study
             participation, or during the study period.

          2. Any type of prior cosmetic treatment to the target area within 6 months of study
             participation.

          3. Any prior invasive cosmetic surgery to the target area, such as liposuction.

          4. Has a pacemaker, internal defibrillator, implantable cardioverter-defibrillator, nerve
             stimulator implant, cochlear implant or any other electronically, magnetically or
             mechanically activated implant.

          5. Has metal implant(s) within the body, such as artificial heart valves.

          6. Significant uncontrolled concurrent illness that in the opinion of the Investigator
             would make the subject unsuitable for inclusion.

          7. History of any disease or condition that could impair wound healing.

          8. History of keloid formation, hypertrophic scarring or abnormal/delayed wound healing.

          9. Skin abnormality in the treatment area that in the opinion of the Investigator would
             make the subject unsuitable for inclusion.

         10. Currently undergoing systemic chemotherapy or radiation treatment for cancer, or
             history of treatment in the target area within 3 months of study participation.

         11. As per the Investigator's discretion, any physical or mental condition which might
             make it unsafe for the subject to participate in this study or a condition that would
             compromise the subject's ability to comply with the study requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Ronan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cutera Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ashish Bhatia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Dermatology Institute of DuPage Medical Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joely Kaufman, MD, FAAD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skin Associates of South Florida</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michaela Bell</last_name>
    <phone>415-657-5722</phone>
    <email>mbell@cutera.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ginger Pocock</last_name>
    <phone>415-657-5702</phone>
    <email>gpocock@cutera.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cutera Research Center</name>
      <address>
        <city>Brisbane</city>
        <state>California</state>
        <zip>94005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mishell San Juan</last_name>
      <phone>415-657-5544</phone>
      <email>msanjuan@cutera.com</email>
    </contact>
    <investigator>
      <last_name>Stephen Ronan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skin Associates of South Florida</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Cazzaniga</last_name>
      <phone>305-443-6606</phone>
      <email>acazzaniga@srinstitute.org</email>
    </contact>
    <investigator>
      <last_name>Joely Kaufman, MD, FAAD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Dermatology Institute of DuPage Medical Group</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60563</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan Childers</last_name>
      <phone>630-547-5040</phone>
      <email>ryanchilders@Dupagemd.com</email>
    </contact>
    <investigator>
      <last_name>Ashish Bhatia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shraddha Desai, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2018</study_first_submitted>
  <study_first_submitted_qc>February 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2018</study_first_posted>
  <last_update_submitted>February 8, 2018</last_update_submitted>
  <last_update_submitted_qc>February 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

